PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15238444-5 2005 This agonist also promotes Raf-1 phosphorylation on serine 338 residue, suggesting increased activation of this protein. Serine 52-58 v-raf-leukemia viral oncogene 1 Mus musculus 27-32 8058342-3 1994 Here we show that Bcl-2 can be co-immunoprecipitated with the serine/threonine-specific Raf-1 kinase both in a mammalian hemopoietic cell 32D.3 and when the two proteins are produced in Sf9 insect cells using recombinant baculoviruses. Serine 62-68 v-raf-leukemia viral oncogene 1 Mus musculus 88-93 12604616-6 2003 As a consequence, there is a reduction in the phosphorylation of Raf-1 at Ser(338), MEK1/2 at Ser(217) and Ser(221), and ERK1/2 at Thr(202) and Tyr(204). Serine 74-77 v-raf-leukemia viral oncogene 1 Mus musculus 65-70 12612072-4 2003 In NIH 3T3 fibroblasts and COS-1 cells, mutation of serine 259 resulted in Raf-1 proteins which activated the MEK/ERK pathway as efficiently as v-Raf. Serine 52-58 v-raf-leukemia viral oncogene 1 Mus musculus 75-80 12612072-4 2003 In NIH 3T3 fibroblasts and COS-1 cells, mutation of serine 259 resulted in Raf-1 proteins which activated the MEK/ERK pathway as efficiently as v-Raf. Serine 52-58 v-raf-leukemia viral oncogene 1 Mus musculus 144-149 11262401-2 2001 Previously, AMPK was reported to phosphorylate serine 621 of Raf-1 in vitro. Serine 47-53 v-raf-leukemia viral oncogene 1 Mus musculus 61-66 11262401-6 2001 Phosphorylation of Raf-1 serine 621, however, was not involved in AMPK-mediated inhibition of Erk cascades. Serine 25-31 v-raf-leukemia viral oncogene 1 Mus musculus 19-24 10684111-7 1997 Raf-1 (74 KDa), with an intrinsic serine (Ser)-threonine (The) kinase activity, becomes hyperphosphorylated after activation which can be followed by gel mobility shift test. Serine 34-40 v-raf-leukemia viral oncogene 1 Mus musculus 0-5 10684111-7 1997 Raf-1 (74 KDa), with an intrinsic serine (Ser)-threonine (The) kinase activity, becomes hyperphosphorylated after activation which can be followed by gel mobility shift test. Serine 42-45 v-raf-leukemia viral oncogene 1 Mus musculus 0-5 7623807-3 1995 Wild-type (His)6- and FLAG-Raf-1 were activated in a Ras- and ATP-dependent manner by transformed membranes; however, Raf-1 proteins that are kinase defective (K375M), that lack an in vivo site(s) of regulatory tyrosine (YY340/341FF) or constitutive serine (S621A) phosphorylation, that do not bind Ras (R89L), or that lack an intact zinc finger (CC165/168SS) were not. Serine 250-256 v-raf-leukemia viral oncogene 1 Mus musculus 118-123 7623807-10 1995 Our findings suggest a model for activation of Raf-1, wherein (i) Raf-1 associates with Ras-GTP, (ii) Raf-1 is activated by tyrosine and/or serine phosphorylation, and (iii) Raf-1 activity is further increased by a membrane cofactor. Serine 140-146 v-raf-leukemia viral oncogene 1 Mus musculus 47-52 15379891-7 2004 Raf-1 may be involved in these effects because oestrogen caused the rapid serine 338 (Ser338) phosphorylation of this protein. Serine 74-80 v-raf-leukemia viral oncogene 1 Mus musculus 0-5 15026317-3 2004 We now show that EPO induces phosphorylation of Raf-1 at serine 338 and within the carboxy-terminal domain, resulting in an electrophoretic mobility change (hyperphosphorylation). Serine 57-63 v-raf-leukemia viral oncogene 1 Mus musculus 48-53 11997508-1 2002 It is widely accepted that cyclic AMP (cAMP) can block cell growth by phosphorylating Raf-1 on serine 43 and inhibiting signaling to extracellular signal-regulated protein kinase. Serine 95-101 v-raf-leukemia viral oncogene 1 Mus musculus 86-91 8321321-5 1993 PKC alpha induces Raf-1 phosphorylation at several sites, including a serine residue at position 499. Serine 70-76 v-raf-leukemia viral oncogene 1 Mus musculus 18-23 8131746-4 1994 In human MEK1, substitution of either serine residue 218 or 222 with alanine completely abolished its activation by epidermal growth factor-stimulated Swiss 3T3 cell lysates or immunoprecipitated c-raf, suggesting that both serine residues are required for MEK1 activation. Serine 38-44 v-raf-leukemia viral oncogene 1 Mus musculus 196-201 8288587-0 1994 Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells. Serine 26-32 v-raf-leukemia viral oncogene 1 Mus musculus 68-73 8288587-7 1994 Purified PKC can phosphorylate Raf-1 serine residues to high stoichiometry in vitro. Serine 37-43 v-raf-leukemia viral oncogene 1 Mus musculus 31-36 8288587-10 1994 Furthermore, PKC-mediated serine phosphorylation is sufficient to activate the enzymatic function of Raf-1 in vitro. Serine 26-32 v-raf-leukemia viral oncogene 1 Mus musculus 101-106 8288587-11 1994 These findings demonstrate that activated PKC can promote hematopoietic cell growth by regulating the enzymatic activity of Raf-1 through direct serine phosphorylation. Serine 145-151 v-raf-leukemia viral oncogene 1 Mus musculus 124-129 8321321-6 1993 Mutation of serine at this position or at residue 259 does not abrogate Raf-1 stimulation by a combination of Ras plus the src tyrosine kinase Lck, but severely impedes Raf-1 activation by PKC alpha. Serine 12-18 v-raf-leukemia viral oncogene 1 Mus musculus 169-174 1741164-7 1992 Subtractive Edman degradation and electrophoretic analysis of the immunoprecipitated tryptic peptide indicated that phosphorylation of the Raf-1 protein occurs at serine 259. Serine 163-169 v-raf-leukemia viral oncogene 1 Mus musculus 139-144 8340422-9 1993 Although PDGF/insulin-stimulated c-Raf-1 Ser/Thr phosphorylation may be necessary to sustain the active state, a role for mitogen-activated protein kinase/extracellular signal-regulated kinase-2 phosphorylation in the initiation of c-Raf-1 activation is unlikely. Serine 41-44 v-raf-leukemia viral oncogene 1 Mus musculus 33-38 18922468-0 2008 CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Serine 28-34 v-raf-leukemia viral oncogene 1 Mus musculus 0-4 1902232-0 1991 Insulin and platelet-derived growth factor stimulate phosphorylation of the c-raf product at serine and threonine residues in intact cells. Serine 93-99 v-raf-leukemia viral oncogene 1 Mus musculus 76-81 21400615-6 2011 Importantly, 5"-NIO inhibited Pin1 phosphorylation at serine 16 induced by EGF or TPA, respectively, resulted in the inhibition of interaction between Pin1 and Raf-1. Serine 54-60 v-raf-leukemia viral oncogene 1 Mus musculus 160-165 20056832-6 2010 Insulin also enhanced the interaction between mitochondrial Raf-1 and Bcl-2 agonist of cell death (Bad), promoting Bad inactivation via its phosphorylation on serine 112. Serine 159-165 v-raf-leukemia viral oncogene 1 Mus musculus 60-65 1700980-3 1990 IL-3 and granulocyte-macrophage colony-stimulating factor induce phosphorylation of c-raf at both serine and tyrosine residues. Serine 98-104 v-raf-leukemia viral oncogene 1 Mus musculus 84-89 34688658-5 2021 Mechanistically, we demonstrate that USP13 physically interacts with, deubiquitinates, and stabilizes serine/threonine kinase Raf1 and thereby sustains Raf1 protein at the posttranslational level to activate the FGF/MEK/ERK pro-differentiation signaling pathway in naive mouse ESCs. Serine 102-108 v-raf-leukemia viral oncogene 1 Mus musculus 126-130 3057494-4 1988 The phosphorylation of the Raf-1 protein occurred primarily on serine and threonine residues. Serine 63-69 v-raf-leukemia viral oncogene 1 Mus musculus 27-32 18922468-4 2008 By creating a kinase-defective version of CRAF in mice or by use of the RAF inhibitor sorafenib, we show that CRAF must first undergo autophosphorylation of serine 621 (S621). Serine 157-163 v-raf-leukemia viral oncogene 1 Mus musculus 42-46 18922468-4 2008 By creating a kinase-defective version of CRAF in mice or by use of the RAF inhibitor sorafenib, we show that CRAF must first undergo autophosphorylation of serine 621 (S621). Serine 157-163 v-raf-leukemia viral oncogene 1 Mus musculus 110-114 18706973-6 2008 We found a dysregulation of cRaf-1 in the cortex of APPswe mice, which showed a 147% increase in the active form phosphorylated at serine 338 and a 40% decrease in the levels of the inactive form of cRaf-1, phospho-cRaf-1[Ser259]. Serine 131-137 v-raf-leukemia viral oncogene 1 Mus musculus 28-34 18006502-7 2008 Inhibiting Raf-1 in beta-cells led to a striking loss of Bad phosphorylation at serine 112 and an increase in the protein levels of both Bad and Bax. Serine 80-86 v-raf-leukemia viral oncogene 1 Mus musculus 11-16 17535812-6 2007 Silencing the expression of either Grb10 or Raf-1 by small interfering RNAs as well as mutagenesis of specific serine residues on Bad, coupled with signaling inhibitor studies, all indicate that Raf-1 and Grb10 are required for the ability of both the phosphatidylinositol 3-kinase/Akt and MAP kinase pathways to modulate the phosphorylation and inactivation of Bad. Serine 111-117 v-raf-leukemia viral oncogene 1 Mus musculus 195-200